Related Experiment Videos
Digoxin pharmacokinetics in premature infants
Pediatric Pharmacology (New York, N.Y.)
|January 1, 1982
Summary
Digoxin pharmacokinetics in premature infants show a prolonged plasma half-life. Clearance and distribution volumes are reduced compared to older patients, impacting drug dosing.
Area of Science:
- Pharmacology
- Neonatal Medicine
- Drug Metabolism
Background:
- Digoxin is a cardiac glycoside used to treat heart failure and arrhythmias.
- Premature infants represent a unique population with distinct physiological characteristics that can affect drug pharmacokinetics.
- Understanding digoxin's behavior in neonates is crucial for safe and effective therapeutic use.
Purpose of the Study:
- To analyze the pharmacokinetic parameters of digoxin in premature infants.
- To compare these parameters with those observed in older patient groups.
Main Methods:
- Six premature infants received a single total digitalizing dose of digoxin (20 microgram/kg).
- Plasma digoxin concentrations were analyzed over time.
- Pharmacokinetic data were modeled using both 2 and 3 exponential models.
Main Results:
- The plasma half-life of digoxin was found to be prolonged in premature infants.
- Key parameters including the volume of the central compartment, total body clearance, volume of distribution, and volume of distribution at steady state were reduced.
- These findings suggest altered drug distribution and elimination in this population.
Conclusions:
- Premature infants exhibit significantly different digoxin pharmacokinetics compared to older individuals.
- Reduced clearance and distribution volumes necessitate careful dose adjustments in neonates.
- Further research is warranted to optimize digoxin dosing strategies for premature infants.